Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation

Clinical Research in Cardiology - Tập 106 - Trang 85-95 - 2016
Philipp Ruile1, Nikolaus Jander1, Philipp Blanke2, Simon Schoechlin1, Jochen Reinöhl3, Michael Gick1, Juergen Rothe1, Mathias Langer4, Jonathon Leipsic2, Heinz-Joachim Buettner1, Franz-Josef Neumann1, Gregor Pache4
1Department of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany
2Center for Heart Valve Innovation, St. Paul’s Hospital and University of British Columbia, Vancouver, Canada
3Department of Cardiology and Angiology I, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany
4Department of Radiology, Section of Cardiovascular Radiology, University of Freiburg, Freiburg im Breisgau, Germany

Tóm tắt

After transcatheter aortic valve implantation, early leaflet thickening, presumably reflecting thrombus, has recently been described on computed tomography angiography (CTA) in ~10% of the patients. We sought to investigate the impact of the antithrombotic regimen on the course of leaflet thickening. The study comprised 51 patients with leaflet thickening. Based on the time period, patients without an established indication for anticoagulation were put on phenprocoumon plus clopidogrel for at least 3 months or on dual antiplatelet therapy with aspirin and clopidogrel. Follow-up CTAs were evaluated for leaflet restriction, assessed by four-point-grading score, and maximal thickness. The anticoagulation and the dual antiplatelet therapy group comprised 29 and 22 patients, respectively. After a median of 86 days, we obtained follow-up CTAs in 22 patients on anticoagulation and in 16 patients on dual antiplatelet therapy. Leaflet thickening progressed in 11 on dual antiplatelet therapy, but always regressed onanticoagulation. The course of leaflet restriction and maximal thickness was significantly different between the two groups (P < 0.001): in the dual antiplatelet therapy group, maximal thickness increased by a mean of 1.37 ± 1.67 mm (P = 0.005) and leaflet restriction score by a median 1[quartiles 0;2] (P = 0.013), whereas in the anticoagulation group, maximal thickness regressed by 2.57 ± 1.52 mm (P < 0.001) and leaflet restriction score decreased by 1[−4;0] (P = 0.001). After a median of 91 days after discontinuation of anticoagulation, CTA performed in ten patients revealed a significant recurrent increase in leaflet restriction score and maximal thickness (P = 0.023, P = 0.007). In the entire cohort, changes in leaflet restriction correlated significantly with changes in transvalvular pressure gradients (r = 0.511, P < 0.001). The course of leaflet restriction was fundamentally different depending on the presence or absence of anticoagulation, with consistent regression under phenprocoumon, but mostly progression under antiplatelet therapy alone. Changes in leaflet restriction were associated with changes in transvalvular pressure gradients.

Tài liệu tham khảo

Pache G, Blanke P, Zeh W et al (2013) Cusp thrombosis after transcatheter aortic valve replacement detected by computed tomography and echocardiography. Eur Heart J 34:3546 Pache G, Schoechlin S, Blanke P et al (2016) Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J 37(28):2263–2271. doi:10.1093/eurheartj/ehv526 Makkar RR, Fontana G, Jilaihawi H et al (2015) Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 373:2015–2024 Leetmaa T, Hansson NC, Leipsic J et al (2015) Early aortic transcatheter heart valve thrombosis: diagnostic value of contrast-enhanced multidetector computed tomography. Circ Cardiovasc Interv 8(4):e001596. doi:10.1161/CIRCINTERVENTIONS.114.001596 Hansson NC, Grove EL, Andersen HR et al (2016) Transcatheter aortic heart valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol 68(19):2059–2069 Cota L, Stabile E, Agrusta M et al (2013) Bioprostheses “thrombosis” after transcatheter aortic valve replacement. J Am Coll Cardiol 61:789–791 Córdoba-Soriano JG, Puri R, Amat-Santos I et al (2015) Valve thrombosis following transcatheter aortic valve implantation: a systematic review. Rev Esp Cardiol Engl Ed 68:198–204 Leetmaa TH, Poulsen SH, Nörgaard BL et al (2014) Two cases of thrombotic stenosis in SAPIEN XT valves after transapical implantation. EuroIntervention 10:270 Lancellotti P, Radermecker MA, Weisz SH et al (2013) Subacute transcatheter CoreValve thrombotic obstruction. Circ Cardiovasc Interv 6:e32–e33 Latib A, Messika-Zeitoun D, Maisano F et al (2013) Reversible edwards sapien XT dysfunction due to prosthesis thrombosis presenting as early structural deterioration. J Am Coll Cardiol 61:787–789 Pislaru SV, Hussain I, Pellikka PA et al (2015) Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg 47(4):725–732 Butnaru A, Shaheen J, Tzivoni D et al (2013) Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. Am J Cardiol 112:1439–1444 Jander N, Kienzle R-P, Kayser G et al (2012) Usefulness of phenprocoumon for the treatment of obstructing thrombus in bioprostheses in the aortic valve position. Am J Cardiol 109:257–262 Jander N, Pache G, Henschke S et al (2013) Diagnosis of obstructive thrombosis in a porcine bioprosthesis in the aortic position by contrast-enhanced ECG-gated computer tomography. Eur Heart J 34:1357 Ye J, Cheung A, Lichtenstein SV, Carere RG, Thompson CR, Pasupati S, Webb JG (2006) Transapical aortic valve implantation in humans. J Thorac Cardiovasc Surg 131:1194–1196 Webb JG, Chandavimol M, Thompson CR et al (2006) Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 113:842–850 Jander N, Sommer H, Pingpoh C et al (2015) The porcine valve type predicts obstructive thrombosis beyond the first three postoperative months in bioprostheses in the aortic position. Int J Cardiol 15(199):90–95 Kappetein AP, Head SJ, Généreux P et al (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 33:2403–2418 Del Trigo M, Muñoz-Garcia AJ, Wijeysundera HC et al (2016) Incidence, timing, and predictors of valve hemodynamic deterioration after transcatheter aortic valve replacement: multicenter registry. J Am Coll Cardiol 67:644–655 Mack MJ, Douglas PS, Holmes DR (2016) Shedding more light on valve thrombosis after transcatheter aortic valve replacement∗. J Am Coll Cardiol 67:656–658 Greason KL, Mathew V, Sarano ME et al (2013) Early transcatheter aortic valve thrombosis. J Card Surg 28:264–266 Tay E, Gurvitch R, Wijesinghe N et al (2011) Valve thrombosis after transcatheter heart valve implantation. EuroIntervention 7:170–171 Trepels T, Martens S, Doss M et al (2009) Thrombotic restenosis after minimally invasive implantation of aortic valve stent. Circulation 120:e23–e24